A detailed history of Frazier Financial Advisors, LLC transactions in Genmab A/S stock. As of the latest transaction made, Frazier Financial Advisors, LLC holds 465 shares of GMAB stock, worth $9,839. This represents 0.01% of its overall portfolio holdings.

Number of Shares
465
Previous 465 -0.0%
Holding current value
$9,839
Previous $11.7 Million 2.99%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$26.43 - $32.77 $3,462 - $4,292
131 Added 39.22%
465 $13.9 Million
Q4 2023

Feb 09, 2024

BUY
$27.94 - $35.44 $9,331 - $11,836
334 New
334 $10.6 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.9B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Frazier Financial Advisors, LLC Portfolio

Follow Frazier Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frazier Financial Advisors, LLC with notifications on news.